Much Covid Symptoms May Be Relieved By Expanded Paxlovid.

Summary: Although its performance varies widely, prolonged training of Paxlovid may temporarily lessen symptoms in some people with long Covid. Of 13 individuals studied, five experienced sustained changes, while others reported momentary or no rewards.

This difficulty highlights the difficulty of managing long Covid, a problem with more than 200 symptoms ranging from mind fog to breathing issues. Experts emphasize the need for more detailed research to identify the patients who might take the most viral medications.

Important Facts:

Combined Benefits: Five out of 13 people received lengthy paxlovid care and sustained developments in their long Covid symptoms.
• Much Covid Challenge: The condition affects 1 in 13 people in the U. S., with over 200 reported signs.
• Potential Research Needed: Research aim to identify genetic mechanisms and patient-specific reactions to treatments.

Origin: UCSF

According to a case series from UC San Francisco experts, Paxlovid extended therapy may help some patients who have long Covid. This treatment option may have potential for some patients who struggle with crippling symptoms. &nbsp,

These findings conflict with recent study that concluded that the antibacterial may treat persistent disease symptoms. More research is needed, according to the creators, to understand which people might gain from the medication and how much it should be given.

The Centers for Disease Control and Prevention ( CDC ) estimates that 17.6 million Americans, or 1 in 13 adults, have long Covid. These individuals exhibit signs that range from mental fog and headaches to breathing and cardiovascular issues for months or even years after their first Covid-19 disease. &nbsp,

” We are about five years into the pandemic, and yet there are not yet any federally-approved remedies for longer Covid”, said&nbsp, Alison Cohen, PhD, MPH, an associate professor of epidemiology and biostatistics at UCSF and first author of the paper.

” This is not a silver bullet, but it may help a lot of people in a meaningful way” .&nbsp,

The research appears Jan. 6 in the&nbsp, Nature&nbsp, publication&nbsp, Communications Medicine.

Conversations with clients reveal that some people find the drug helpful.

In June, a randomised controlled clinical trial of a 15-day program of nirmatrelvir/ritonavir, the medicine mix marketed as Paxlovid, concluded that it was safe, although it did not lessen long Covid symptoms. Further study may provide benefits for people with particular symptoms or at various dosages, according to the scientists.

The UCSF staff collaborated with long Covid people, some of whom are users of the Patient-Led Research Collaborative, a group of people with long Covid and another associated autoimmune conditions who are also experts.

The researchers examined the effects of taking a longer course of Paxlovid on subjects with particular indications or stages of their illness to see if it does work in people with different symptoms. Additionally, they looked at the activities of those who contracted various SARS-CoV-2 strains.

Five of the 13 study participants reported lasting indicators improvement. People experienced momentary pardons, and some had no progress. Treatment measures varied, but some took Paxlovid for 15 weeks. &nbsp,

For instance, a 56-year-old person who developed long Covid at the start of the crisis was plagued for more than two times with fatigue, headaches, sensitivity, brain fog, training hatred, elevated heart rate and joint pain. He took Paxlovid for five days in September 2022, but his signs didn’t change.

Three months later, he began taking it for 15 times, and he reported that both his physical and cognitive symptoms improved. &nbsp,

And a 45-year-old person who developed long Covid in January of 2022 experienced stress, breathing difficulties, chest pain, weight reduction and headache for months after her illness.

A five-day program of Paxlovid in October of 2022 gave her a three-day relief from her symptoms. However, it was completely unaffected by her symptoms when she began a 15-day sure the following month. &nbsp,

With more than 200 signs ascribed to the problem, long Covid has remained difficult to define, evaluate or address. Researchers are still trying to understand the natural mechanisms that underlie the problem, and UCSF has launched&nbsp, the country’s first long Covid cell bank. &nbsp,

One of the most crucial questions for the field is” that long Covid is complex,” said study co-author Michael Peluso, MD, principal investigator of the UCSF long COVID research program and infectious disease researcher in the UCSF School of Medicine.” Understanding why some people benefit so remarkably from antiviral treatment while others don’t is one of the most important questions for the field.

” We are going to need to accept that complexity to find solutions for the millions of people who have this condition,” he said.

Authors: &nbsp, Additional co-authors are associated with the Patient-Led Research Collaborative, a group of long Covid patients and individuals with associated illnesses who are also researchers. &nbsp,

Funding: &nbsp, &nbsp, The authors received no funding for this work.

About this Long news story about neuropharmacology and COVID research

Author: Victoria Colliver
Source: UCSF
Contact: Victoria Colliver – UCSF
Image: The image is credited to Neuroscience News

Original Research: Open access.
” Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series” by Alison Cohen et al. Communications Medicine

---

Abstract

Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series

Background

Prior case series suggest that a 5-day course of oral Paxlovid ( nirmatrelvir/ritonavir ) benefits some people with Long COVID, within and/or outside of the context of an acute reinfection. To the best of our knowledge, there have been no prior case series of people with Long COVID who have attempted longer courses of nirmatrelvir/ritonavir.

Methods

We documented a case series of 13 individuals with Long COVID who initiated extended courses ( &gt, 5 days, range: 7.5–30 days ) of oral nirmatrelvir/ritonavir outside ( n = 11 ) of and within ( n = 2 ) the context of an acute SARS-CoV-2 infection. Participants reported on symptoms and health experiences before, during, and after their use of nirmatrelvir/ritonavir.

Results

Among those who take an extended course of nirmatrelvir/ritonavir outside of the context of an acute infection, some experience a meaningful reduction in symptoms, although not all benefits persist. Others experience no effect on symptoms. One participant sat down too early because of severe stomach pain.

For the two participants who took an extended course of nirmatrelvir/ritonavir within the context of an acute reinfection, both report eventually returning to their pre-re-infection baseline.

Conclusions

Some people with Long COVID may benefit from extended courses of nirmatrelvir/ritonavir but not others. In order to inform clinical recommendations for using nirmatrelvir/ritonavir and/or other antivirals as a potential treatment for Long COVID, we encourage researchers to study how and why some people benefit from nirmatrelvir/ritonavir and what course length is most effective.